Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Taxes (2016 - 2017)

Historic Change in Taxes for Amphastar Pharmaceuticals (AMPH) over the last 5 years, with Q3 2017 value amounting to -$2.5 million.

  • Amphastar Pharmaceuticals' Change in Taxes fell 35128.68% to -$2.5 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$5.8 million, marking a year-over-year decrease of 23687.59%. This contributed to the annual value of -$92000.0 for FY2015, which is 11645.8% down from last year.
  • Amphastar Pharmaceuticals' Change in Taxes amounted to -$2.5 million in Q3 2017, which was down 35128.68% from -$3.2 million recorded in Q2 2017.
  • In the past 5 years, Amphastar Pharmaceuticals' Change in Taxes registered a high of $6.0 million during Q4 2014, and its lowest value of -$7.3 million during Q3 2014.
  • Moreover, its 5-year median value for Change in Taxes was -$85500.0 (2013), whereas its average is -$314500.0.
  • Its Change in Taxes has fluctuated over the past 5 years, first surged by 1513750.0% in 2014, then plummeted by 35128.68% in 2017.
  • Amphastar Pharmaceuticals' Change in Taxes (Quarter) stood at -$40000.0 in 2013, then skyrocketed by 15137.5% to $6.0 million in 2014, then tumbled by 83.52% to $991000.0 in 2015, then tumbled by 154.89% to -$544000.0 in 2016, then plummeted by 351.29% to -$2.5 million in 2017.
  • Its Change in Taxes was -$2.5 million in Q3 2017, compared to -$3.2 million in Q2 2017 and $394000.0 in Q1 2017.